NEW YORK (GenomeWeb News) – Microchip Biotechnologies said today that it has licensed certain patents from General Electric’s GE Healthcare division that cover design and methods for creating integrated fluidic microchip devices.
MBI said the license would “significantly enhance” its intellectual property portfolio supporting development of lab-on-a-chip devices. The Dublin, Calif.-based firm said that it would use the licensed technology to develop and market "sample-to-answer" systems for genomic analyses and molecular diagnostics.
"Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics,” said Stevan Jovanovich, president and CEO of MBI, in a statement.
Financial terms of the alliance were not disclosed.